Healthcare
The GLP-1 question nobody in pharma is asking
The industry conversation on GLP-1s is mostly about supply, pricing, and label expansion. All legitimate questions. None of them the most interesting one.
The most interesting question is what GLP-1s have proven about patient behaviour — and what that implies for every other category that has assumed patients won't pay out of pocket, won't self-initiate, and won't pressure their physician for a specific molecule.
What the evidence actually shows
Millions of patients, in categories historically treated with low engagement, have done three things in under three years:
They've identified a specific molecule by brand name. They've actively asked their GP for it. They've paid for it in cash when it wasn't funded. At scale.
This is a new behavioural pattern in therapy areas outside oncology and rare disease. And it's not limited to obesity. Patients in adjacent cardio-metabolic indications are starting to arrive at the consultation already knowing what they want.
What this should be changing, but mostly isn't
If patients can identify a specific molecule, ask for it by name, and pay out of pocket, the strategic centre of gravity shifts. The physician is no longer the sole decision-maker. The payer is no longer the sole gatekeeper. The patient, equipped with TikTok, Reddit, and a GLP-1 prescription from a friend, becomes a commercial force in their own right.
Most brand plans in adjacent categories are still written as if the physician is the primary audience, the payer is the primary gate, and the patient is a passive endpoint. The plans are organised around a world that is quietly becoming less true.
The question to sit with
If patients in your therapy area decided, next year, to behave the way obesity patients have behaved for the last three — asking for a specific brand by name, paying out of pocket, using social channels to coordinate demand — would your brand be ready?
Most of the teams we work with answer this honestly: no. The channel strategy isn't built for it. The medical information function isn't built for it. The patient-services model isn't built for it. The commercial forecast doesn't assume it.
Which means the real GLP-1 lesson isn't about GLP-1s. It's about whether the commercial architecture of a brand is designed for the patient it assumes, or for the patient it might actually get.